Drug Profile
DCB WH2
Alternative Names: DCB-WH2Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Developer Development Center for Biotechnology; Oneness Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Wounds
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Wounds in Taiwan (unspecified route), prior to August 2023 (Oneness Biotech pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Wounds in Taiwan
- 18 Jan 2016 Preclinical trials in Wounds in Taiwan (unspecified route)